PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites

Darren R. Tyson, John T. Swarthout, Stephen C. Jefcoat, Nicola Partridge

Research output: Contribution to journalArticle

Abstract

We have previously shown that PTH induction of c-fos expression in the rat osteoblastic cell line UMR 106-01 requires the phosphorylation of cAMP response element-binding protein (CREB) at serine 133. Here we show that this event is not sufficient for induced transcriptional activity in UMR cells. Serine 129, but not the casein kinase II sites (serines 108, 111, 114, 117, and 121), also plays a role in the activation of CREB. First, by metabolically labeling an epitope-tagged CREB, we determined that, in addition to serine 133, other residues are phosphorylated in vivo. Using mutational analysis of a GAL4-CREB reporter system we demonstrate that serines 129 and 133 are both required for PTH-induced transcriptional activity, whereas the casein kinase II sites are not. Furthermore, PTH failed to induce transcriptional activity of GAL4-CREB in cells treated with genistein, a general tyrosine kinase inhibitor known to inhibit glycogen synthase kinase-3 (GSK-3) activity, or LiCl, the most specific GSK-3-inhibiting agent known, strongly implicating GSK-3β in this process. Importantly, although genistein and LiCl each inhibit GSK-3β activity, neither prevented the phosphorylation of serine 133 induced by PTH. Lastly, when serine 129 is replaced with a negatively charged aspartic acid, LiCl has no effect on the PTH-induced trans-activation of CREB. We propose that GSK-3β phosphorylates CREB at serine 129 and thus is required for the increased transcriptional activity of CREB in response to PTH.

Original languageEnglish (US)
Pages (from-to)674-682
Number of pages9
JournalEndocrinology
Volume143
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Glycogen Synthase Kinase 3
Casein Kinase II
Cyclic AMP Response Element-Binding Protein
Serine
Genistein
Phosphorylation
Aspartic Acid
Protein-Tyrosine Kinases
Epitopes
Cell Line

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites. / Tyson, Darren R.; Swarthout, John T.; Jefcoat, Stephen C.; Partridge, Nicola.

In: Endocrinology, Vol. 143, No. 2, 2002, p. 674-682.

Research output: Contribution to journalArticle

@article{7665be62339647b9a10851ca5b11447a,
title = "PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites",
abstract = "We have previously shown that PTH induction of c-fos expression in the rat osteoblastic cell line UMR 106-01 requires the phosphorylation of cAMP response element-binding protein (CREB) at serine 133. Here we show that this event is not sufficient for induced transcriptional activity in UMR cells. Serine 129, but not the casein kinase II sites (serines 108, 111, 114, 117, and 121), also plays a role in the activation of CREB. First, by metabolically labeling an epitope-tagged CREB, we determined that, in addition to serine 133, other residues are phosphorylated in vivo. Using mutational analysis of a GAL4-CREB reporter system we demonstrate that serines 129 and 133 are both required for PTH-induced transcriptional activity, whereas the casein kinase II sites are not. Furthermore, PTH failed to induce transcriptional activity of GAL4-CREB in cells treated with genistein, a general tyrosine kinase inhibitor known to inhibit glycogen synthase kinase-3 (GSK-3) activity, or LiCl, the most specific GSK-3-inhibiting agent known, strongly implicating GSK-3β in this process. Importantly, although genistein and LiCl each inhibit GSK-3β activity, neither prevented the phosphorylation of serine 133 induced by PTH. Lastly, when serine 129 is replaced with a negatively charged aspartic acid, LiCl has no effect on the PTH-induced trans-activation of CREB. We propose that GSK-3β phosphorylates CREB at serine 129 and thus is required for the increased transcriptional activity of CREB in response to PTH.",
author = "Tyson, {Darren R.} and Swarthout, {John T.} and Jefcoat, {Stephen C.} and Nicola Partridge",
year = "2002",
doi = "10.1210/en.143.2.674",
language = "English (US)",
volume = "143",
pages = "674--682",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites

AU - Tyson, Darren R.

AU - Swarthout, John T.

AU - Jefcoat, Stephen C.

AU - Partridge, Nicola

PY - 2002

Y1 - 2002

N2 - We have previously shown that PTH induction of c-fos expression in the rat osteoblastic cell line UMR 106-01 requires the phosphorylation of cAMP response element-binding protein (CREB) at serine 133. Here we show that this event is not sufficient for induced transcriptional activity in UMR cells. Serine 129, but not the casein kinase II sites (serines 108, 111, 114, 117, and 121), also plays a role in the activation of CREB. First, by metabolically labeling an epitope-tagged CREB, we determined that, in addition to serine 133, other residues are phosphorylated in vivo. Using mutational analysis of a GAL4-CREB reporter system we demonstrate that serines 129 and 133 are both required for PTH-induced transcriptional activity, whereas the casein kinase II sites are not. Furthermore, PTH failed to induce transcriptional activity of GAL4-CREB in cells treated with genistein, a general tyrosine kinase inhibitor known to inhibit glycogen synthase kinase-3 (GSK-3) activity, or LiCl, the most specific GSK-3-inhibiting agent known, strongly implicating GSK-3β in this process. Importantly, although genistein and LiCl each inhibit GSK-3β activity, neither prevented the phosphorylation of serine 133 induced by PTH. Lastly, when serine 129 is replaced with a negatively charged aspartic acid, LiCl has no effect on the PTH-induced trans-activation of CREB. We propose that GSK-3β phosphorylates CREB at serine 129 and thus is required for the increased transcriptional activity of CREB in response to PTH.

AB - We have previously shown that PTH induction of c-fos expression in the rat osteoblastic cell line UMR 106-01 requires the phosphorylation of cAMP response element-binding protein (CREB) at serine 133. Here we show that this event is not sufficient for induced transcriptional activity in UMR cells. Serine 129, but not the casein kinase II sites (serines 108, 111, 114, 117, and 121), also plays a role in the activation of CREB. First, by metabolically labeling an epitope-tagged CREB, we determined that, in addition to serine 133, other residues are phosphorylated in vivo. Using mutational analysis of a GAL4-CREB reporter system we demonstrate that serines 129 and 133 are both required for PTH-induced transcriptional activity, whereas the casein kinase II sites are not. Furthermore, PTH failed to induce transcriptional activity of GAL4-CREB in cells treated with genistein, a general tyrosine kinase inhibitor known to inhibit glycogen synthase kinase-3 (GSK-3) activity, or LiCl, the most specific GSK-3-inhibiting agent known, strongly implicating GSK-3β in this process. Importantly, although genistein and LiCl each inhibit GSK-3β activity, neither prevented the phosphorylation of serine 133 induced by PTH. Lastly, when serine 129 is replaced with a negatively charged aspartic acid, LiCl has no effect on the PTH-induced trans-activation of CREB. We propose that GSK-3β phosphorylates CREB at serine 129 and thus is required for the increased transcriptional activity of CREB in response to PTH.

UR - http://www.scopus.com/inward/record.url?scp=0036157857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036157857&partnerID=8YFLogxK

U2 - 10.1210/en.143.2.674

DO - 10.1210/en.143.2.674

M3 - Article

C2 - 11796524

AN - SCOPUS:0036157857

VL - 143

SP - 674

EP - 682

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 2

ER -